Inactive Instrument

Highlights ImmunoCellular Therapeutics Ltd Nyse

Equities

US4525362046

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

EOM Pharmaceutical Holdings Announces Topline Results of Its Covid-19 Clinical Trial of Eom613 in Brazil	23-09-06	CI
EOM Pharmaceuticals Holdings, Inc. has withdrawn its IPO in the amount of $15 million.	23-08-02	CI
EOM Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-12-20	CI
EOM Pharmaceuticals Holdings, Inc. has filed an IPO in the amount of $25 million.	22-06-24	CI
EOM Pharmaceuticals, Inc. And Immunocellular Therapeutics, Ltd. Announce Entry Into And Close Of Definitive Merger Agreement	21-12-02	PR
EOM Pharmaceuticals, Inc. acquired ImmunoCellular Therapeutics, Ltd. in a reverse merger transaction.	21-12-01	CI
Reverse Split: 1 of 10	20-09-15	FA
ImmunoCellular Therapeutics, Ltd. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2018	18-08-16	CI
ImmunoCellular Therapeutics, Ltd. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2018	18-05-14	CI
ImmunoCellular Therapeutics, Ltd. Announces Achievement of Next Key Milestone in Stem-to-T-Cell Research Immuno-Oncology Program	18-04-12	CI
ImmunoCellular Therapeutics, Ltd. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2017	18-03-13	CI
ImmunoCellular Therapeutics, Ltd. Achieves Stem-to-T-Cell Research Immuno-Oncology Program	17-12-13	CI
ImmunoCellular Therapeutics, Ltd. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017	17-11-21	CI
Immunocellular Therapeutics, Ltd. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2017	17-08-14	CI
ImmunoCellular Therapeutics Provides Update on Strategic Review and Decision to Suspend Further Patient Randomization for ICT-107 Phase 3 Trial	17-06-21	CI
ImmunoCellular Therapeutics, Ltd. Announces Data from ICT-121 Phase 1 Trial in Recurrent Glioblastoma at ASCO 2017	17-06-05	CI
ImmunoCellular Therapeutics, Ltd. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2017	17-05-15	CI
ImmunoCellular Therapeutics and Memgen Announce Letter of Intent for Potential Joint Immuno-Oncology Collaboration	17-03-23	CI
ImmunoCellular Therapeutics, Ltd. Announces Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2016	17-03-09	CI
ImmunoCellular Seeks Acquisitions	17-03-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights ImmunoCellular Therapeutics Ltd Nyse

Equities

US4525362046

Highlights

Filters